September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Comparison of anti-VEGF ranibizumabR and afliberceptR : a 18 months, real-life study in naïve patients
Author Affiliations & Notes
  • Arnaud George
    Ophthalmologie, GLOB, PLERIN, France
  • Valérie Reitzer
    Ophthalmologie, GLOB, PLERIN, France
  • Jean Paul Bellamy
    Ophthalmologie, GLOB, PLERIN, France
  • Footnotes
    Commercial Relationships   Arnaud George, BAYER (R), NOVARTIS (R); Valérie Reitzer, None; Jean Paul Bellamy, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 539. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arnaud George, Valérie Reitzer, Jean Paul Bellamy; Comparison of anti-VEGF ranibizumabR and afliberceptR : a 18 months, real-life study in naïve patients. Invest. Ophthalmol. Vis. Sci. 2016;57(12):539.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To compare the evolution in visual acuity, anatomy and number of intravitreal injections (IVT) in two cohorts of naïve wet age-related macular degeneration (wAMD) patients, treated either by ranibizumabR or afliberceptR, in the real life, in a French private practice center, at baseline, 12 and 18 months.

Methods : We enrolled two cohorts of 14 naïve patients, one treated by ranibizumabR, the other by afliberceptR for wAMD. No selection was realized, the only criteria of exclusion was precedent treatment for wet AMD in the same eye. We retrospectively reviewed the charts of the patients treated by anti VEGF. Following data were collected at baseline,12 and 18 months : age, sex, visual acuity, central retinal thickness (CRT, as measured by spectral-domain Optical Coherence Tomography), presence or not of pigment epithelial detachment (PED), number of IVT. We collected the data from all patients at 18 months.

Results : No statistical significant difference (p>0.5) was found for the following criteria :
- demographics
- number of IVT at 12 and 18 months ; a trend for more IVT was found for afliberceptR.
- visual acuity was slightly better at baseline in the ranibizumabR group.
- CRT was more important in afliberceptR group at baseline.
- at 12 months, decrease in ECR was higher in afliberceptR group.
- at 18 months, decrease in ECR was higher in ranibizumabR group
- same results for PED at 12 and 18 months.

Conclusions : In this real-life study, we confirmed the results of the pivotal studies, i.e no statistical differences between the two anti-VEGF molecules routinely in use, ranibizumabR and afliberceptR. We found trends for a slight better diminution of CRT at 12 months for afliberceptR, but no confirmation at 18 months. Gain of visual acuity was mostly acquired at 12 months, with stabilization at 18 months. No statistical difference was found for number of IVT, for a pro renata protocol.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.